Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer 

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement